bioAffinity Technologies, Inc.
BIAFW · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,362 | $2,532 | $5 | $0 |
| % Growth | 269.7% | 52,617.1% | – | – |
| Cost of Goods Sold | $5,983 | $1,741 | $0 | $5 |
| Gross Profit | $3,379 | $792 | $4 | -$5 |
| % Margin | 36.1% | 31.3% | 90.3% | – |
| R&D Expenses | $1,783 | $1,725 | $1,524 | $1,326 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $9,943 | $6,791 | $2,481 | $876 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $606 | $250 | $10 | $0 |
| Operating Expenses | $12,332 | $8,765 | $4,015 | $2,202 |
| Operating Income | -$8,953 | -$7,973 | -$4,011 | -$2,207 |
| % Margin | -95.6% | -314.9% | -83,511.5% | – |
| Other Income/Exp. Net | -$75 | $57 | -$4,141 | -$4,118 |
| Pre-Tax Income | -$9,028 | -$7,916 | -$8,152 | -$6,324 |
| Tax Expense | $12 | $21 | $2 | $2 |
| Net Income | -$9,040 | -$7,937 | -$8,154 | -$6,326 |
| % Margin | -96.6% | -313.5% | -169,771.2% | – |
| EPS | -22.5 | -27.3 | -54.3 | -25.8 |
| % Growth | 17.6% | 49.7% | -110.5% | – |
| EPS Diluted | -22.5 | -27.3 | -54.3 | -25.8 |
| Weighted Avg Shares Out | 404 | 292 | 150 | 246 |
| Weighted Avg Shares Out Dil | 404 | 292 | 150 | 246 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18 | $122 | $47 | $0 |
| Interest Expense | $92 | $37 | $2,533 | $1,002 |
| Depreciation & Amortization | $606 | $250 | $10 | $5 |
| EBITDA | -$8,330 | -$7,629 | -$5,609 | -$5,318 |
| % Margin | -89% | -301.3% | -116,777.7% | – |